Prostaglandin D2
Based on 4 publication(s) in Google Scholar
Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.5%
- CAS No.: 41598-07-6
- Formule: C20H32O5
- Masse moléculaire:352.47
-
Stockage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Prostaglandin D2
More
Customer Validation & Images
-
RT-PCR
-
WB
-
IHC
-
Flow Cytometry
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
DP |
Human Endogenous Metabolite |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male WT and A2AR KO mice of the inbred C57BL/6 strain (weighing 23-27 g, 11-13 weeks old)[1]
-
Dosage:5, 10, 20, or 50 pmol/min
-
Administration:Infused into the lateral ventricle; for 6 hours between 20:00 and 2:00
-
Result:Induced sleep-wake profiles.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 41598-07-6
-
Appearance Solid
-
Masse moléculaire 352.47
-
Formule C20H32O5
-
Color White to light yellow
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H]([C@@H](O)CC1=O)C/C=C\CCCC(O)=O
-
Synonyms
PGD2
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Structural insights into the mechanism of activation and inhibition of the prostaglandin D2 receptor 1. [Abstract]2025 Oct 8;16(1):8944. PMID: 41062467 -
Cells
L-PGDS-PGD2-DP1 Axis Regulates Phagocytosis by CD36+ MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke. [Abstract]2024 Oct 20;13(20):1737. PMID: 39451255
Prostaglandin D2 purchased from MedChemExpress. Usage Cited in: Cells. 2024 Oct 20;13(20):1737. [Abstract]
RT-qPCR for CD36 levels in MGs/MΦs treated with various concentrations of Prostaglandin D2 (PGD2) (0.1-2.5 μM; 3 days). * p < 0.05 among groups, n = 3 for each group. Abbreviations: MGs/MΦs, microglia/macrophages.
Prostaglandin D2 purchased from MedChemExpress. Usage Cited in: Cells. 2024 Oct 20;13(20):1737. [Abstract]
WB analysis for CD36 levels in MGs/MΦs treated with various concentrations of Prostaglandin D2 (PGD2) (0.1-2.5 μM; 3 days). Abbreviations: MGs/MΦs, microglia/macrophages.
Prostaglandin D2 purchased from MedChemExpress. Usage Cited in: Cells. 2024 Oct 20;13(20):1737. [Abstract]
Immunohistochemistry showing microbead uptake in CD11b+ MGs/MΦs treated without Prostaglandin D2 (PGD2) (2.5 μM; 3 days) (control) (A) or with PGD2 (B) (CD11b [(A,B): red]; DAPI [(A,B): blue]). Immunohistochemistry showed the uptake of FITC+ microbeads in both control CD11b+ MGs/MΦs and PGD2-treated CD11b+ MGs/MΦs, and FITC+ microbead uptake was obviously increased in PGD2-treated CD11b+ MGs/MΦs compared to the control.
Prostaglandin D2 purchased from MedChemExpress. Usage Cited in: Cells. 2024 Oct 20;13(20):1737. [Abstract]
FACS analysis. The microbead uptake was significantly higher in Prostaglandin D2 (PGD2) (2.5 μM; 3 days)-treated MGs/MΦs relative to the control MGs/MΦs.
-
Int J Mol Sci
Prostaglandins Regulate Urinary Purines by Modulating Soluble Nucleotidase Release in the Bladder Lumen. [Abstract]2025 Aug 19;26(16):8023. PMID: 40869346 -
ACS Pharmacol Transl Sci
Ultrasensitive Profiling of Arachidonic Acid Metabolites Based on 5‑(Diisopropylamino)amylamine Derivatization-Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry. [Abstract]2025 Oct 4;8(11):4095-4106. PMID: 41262585
Solvant et solubilité
Ethanol : 75 mg/mL (212.78 mM; Need ultrasonic and warming)
DMSO : 50 mg/mL (141.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.09 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.55 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.55 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Suzuki F, et al. Transport of prostaglandin D2 into brain. Brain Res. 1986 Oct 22;385(2):321-8. [Content Brief]
[2]. Zhang BJ, et al. Adenosine A2A receptor deficiency attenuates the somnogenic effect of prostaglandin D2 in mice. Acta Pharmacol Sin. 2017 Apr;38(4):469-476. [Content Brief]
[3]. Kida T, et al. Prostaglandin D2 Attenuates NSC 125066-Induced Lung Inflammation and Pulmonary Fibrosis. PLoS One. 2016 Dec 19;11(12):e0167729. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.8371 mL | 14.1856 mL | 28.3712 mL | 70.9280 mL |
| 5 mM | 0.5674 mL | 2.8371 mL | 5.6742 mL | 14.1856 mL | |
| 10 mM | 0.2837 mL | 1.4186 mL | 2.8371 mL | 7.0928 mL | |
| 15 mM | 0.1891 mL | 0.9457 mL | 1.8914 mL | 4.7285 mL | |
| 20 mM | 0.1419 mL | 0.7093 mL | 1.4186 mL | 3.5464 mL | |
| 25 mM | 0.1135 mL | 0.5674 mL | 1.1348 mL | 2.8371 mL | |
| 30 mM | 0.0946 mL | 0.4729 mL | 0.9457 mL | 2.3643 mL | |
| 40 mM | 0.0709 mL | 0.3546 mL | 0.7093 mL | 1.7732 mL | |
| 50 mM | 0.0567 mL | 0.2837 mL | 0.5674 mL | 1.4186 mL | |
| 60 mM | 0.0473 mL | 0.2364 mL | 0.4729 mL | 1.1821 mL | |
| 80 mM | 0.0355 mL | 0.1773 mL | 0.3546 mL | 0.8866 mL | |
| 100 mM | 0.0284 mL | 0.1419 mL | 0.2837 mL | 0.7093 mL |
Prostaglandin D2 Related Classifications
HY-101988 Related Classifications
Powered by Bioz